| 0000-00-00 |
|
|
|
External link to document |
| 2019-09-18 |
1 |
Complaint |
6,340,475 (‘475 patent) 9/16/2016
20 6,635,280 (‘280 patent) …Book patent (the ‘692 patent), as well as two non-Orange Book listed patents
20 (the ‘667 patent and…listed patent(s) and/or the patent is
2 invalid and unenforceable. Simply by listing the patents in the…and U.S. Patent No. 8,329,215 (“the ‘215 patent”)).
21 191. The ‘215 patent, like the ‘667…plaintiffs in the
8 patent lawsuit, Assertio/Santarus, to the defendant in the patent lawsuit, Lupin. Lupin |
External link to document |
| 2020-03-05 |
188 |
Order on Motion to Dismiss |
four relevant patents: U.S. Patent Nos.
21 6,340,475; 6,635,280; 6,488,962… 16 for the patent barrier remains. New brand-drug applicants must list the patents (if any) covering…brand drug, that the relevant patents have expired, or that such patents are invalid or will not be
…infringe the patents
4 because it designed around the patents using a… the patent suit, Lupin would stop challenging the
18 patent, and |
External link to document |
| 2020-04-09 |
226 |
Amended Complaint |
Date Expiration Date
11 6,340,475 (’475 patent) March 29, 1999 January…Book patent (the ’692 patent) as well as two non-
28 Orange Book listed patents (the ’667 patent and…Assertio could not patent the drug itself. Instead, Assertio
13 obtained four patents covering extended-release…Lupin would infringe its patents. But Lupin had designed around Assertio’s patents;
6 indeed, before … would not infringe
7 Assertio’s patents and why the patents were invalid.
8 6. Sun |
External link to document |
| 2020-08-15 |
347 |
Order on Motion to Certify Class |
four relevant patents: U.S. Patent Nos.
10 6,340,475; 6,635,280; 6,488,962…analogous anticompetitive behavior, patent misuse, by holding a patent
…from an alleged reverse-payment settlement of a patent
17 infringement…restating. This case arises from a perversion of the patent and pharmaceutical-
…
4 Patents covering the brand drug can still spoil the fun |
External link to document |
| 2021-05-06 |
537 |
Order on Motion for Partial Summary Judgment AND Order on Administrative Motion to File Under Seal AND Order on Administrative Motion to File Under Seal AND Order on Administrative Motion to File Under Seal |
25 United States Patent Nos. 6,340,475 and 6,635,280, which expired in September…’475, ’280, and ’962 patents (it also asserted but later dropped the ’340 patent).
…This argument runs afoul of patent fundamentals. True, we presume a patent’s validity. See
…within the scope of the patent. The royalty payment from the licensee to the patent owner
… 19 In a secret pharmaceutical-patent infringement settlement agreement, concealed from |
External link to document |
| 2021-08-25 |
593 |
Order on Administrative Motion to File Under Seal AND Order on Administrative Motion to File Under Seal AND Order on Administrative Motion to File Under Seal AND Order on Motion for Miscellaneous Relief AND Order on Motion for Miscellaneous Relief AND Order on Administrative Motion to File Under Seal AND Order on Motion for Miscellaneous Relief AND Order on Motion for Miscellaneous Relief AND Order on Motion for Miscellaneous Relief AND Order on Motion for Miscellaneous Relief |
equivalents, for U.S. Patent Nos. 6,340,475 (“the ’475 patent”), 6,635,280 (“the ’280 patent”),
…475, ’280, and ’962 patents, as well as U.S. Patent Nos. 7,736,667 (“the ’667 patent”) and
Northern District… 7 the entire corporate-patent lifecycle, handling everything from patent prosecution to advising
…on the ’962 patent would jump to 85 to 90% if Lupin prevailed on the ’475 and ’280 patents
… 26 patent attorney at the time of the Lupin settlement would have evaluated the patent litigation |
External link to document |
